Decipher Labs Ltd
Incorporated in 1986, Decipher Labs Ltd deals in pharma and consultancy business.[1]
- Market Cap ₹ 9.85 Cr.
- Current Price ₹ 9.75
- High / Low ₹ 17.2 / 9.00
- Stock P/E
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE -4.67 %
- ROE 1.16 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.51 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -1.18% over past five years.
- Promoter holding is low: 16.4%
- Company has a low return on equity of 3.66% over last 3 years.
- Working capital days have increased from 115 days to 247 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 1.02 | 8.06 | 23.99 | 55.56 | 65.32 | 45.57 | 35.88 | 22.61 | 16.53 | |
| 0.95 | 7.61 | 21.47 | 52.08 | 59.29 | 49.74 | 36.56 | 24.50 | 26.94 | |
| Operating Profit | 0.07 | 0.45 | 2.52 | 3.48 | 6.03 | -4.17 | -0.68 | -1.89 | -10.41 |
| OPM % | 6.86% | 5.58% | 10.50% | 6.26% | 9.23% | -9.15% | -1.90% | -8.36% | -62.98% |
| 0.11 | 0.00 | 0.27 | 0.65 | 7.67 | 0.92 | 0.16 | -4.02 | 1.07 | |
| Interest | 0.00 | 0.01 | 0.77 | 1.17 | 0.48 | 0.48 | 0.24 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.56 | 0.82 | 0.87 | 0.43 | 0.45 | 0.48 | 0.50 |
| Profit before tax | 0.18 | 0.44 | 1.46 | 2.14 | 12.35 | -4.16 | -1.21 | -6.39 | -9.84 |
| Tax % | 0.00% | 9.09% | 25.34% | 34.58% | 7.85% | -35.58% | 38.02% | -20.50% | |
| 0.18 | 0.41 | 1.10 | 1.40 | 11.38 | -2.68 | -1.68 | -5.08 | -8.11 | |
| EPS in Rs | 0.22 | 0.51 | 1.09 | 1.39 | 11.27 | -2.65 | -1.66 | -5.03 | -8.03 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -30% |
| TTM: | -49% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -25% |
| 3 Years: | -72% |
| TTM: | -1077% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -20% |
| 3 Years: | -31% |
| 1 Year: | -40% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 4% |
| Last Year: | 1% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.00 | 8.00 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 | 10.10 |
| Reserves | -5.88 | -5.47 | 2.46 | 3.59 | 14.07 | 13.11 | 11.76 | 12.76 | 9.04 |
| 0.13 | 0.20 | 11.28 | 16.39 | 10.32 | 0.95 | 0.00 | 0.24 | 0.43 | |
| 0.71 | 3.61 | 11.55 | 8.64 | 7.46 | 4.01 | 11.77 | 2.66 | 4.19 | |
| Total Liabilities | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
| 0.00 | 0.01 | 4.98 | 4.43 | 2.83 | 3.31 | 2.91 | 2.54 | 2.67 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.26 | 3.76 | 3.39 | 0.26 | 0.00 |
| 2.96 | 6.33 | 30.41 | 34.29 | 38.86 | 21.10 | 27.33 | 22.96 | 21.09 | |
| Total Assets | 2.96 | 6.34 | 35.39 | 38.72 | 41.95 | 28.17 | 33.63 | 25.76 | 23.76 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| -0.10 | 0.23 | -15.18 | 1.83 | 8.26 | -1.56 | 4.85 | -9.82 | |
| 0.00 | -0.02 | -0.01 | -0.31 | -1.13 | -4.28 | -1.79 | 3.07 | |
| 0.09 | 0.07 | 16.36 | 3.99 | 1.30 | -2.15 | -1.17 | 0.24 | |
| Net Cash Flow | -0.01 | 0.28 | 1.17 | 5.51 | 8.43 | -7.99 | 1.90 | -6.51 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 211.13 | 156.69 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Inventory Days | 91.25 | 19.70 | 0.00 | |||||
| Days Payable | 511.00 | 192.66 | ||||||
| Cash Conversion Cycle | -208.62 | -16.27 | 222.44 | 76.67 | 71.47 | 78.90 | 79.35 | 68.12 |
| Working Capital Days | 751.47 | 99.63 | -2.13 | -11.50 | 65.43 | 61.67 | 36.52 | 247.48 |
| ROCE % | 18.07% | 16.79% | 12.28% | 39.74% | 9.45% | -3.09% | -4.67% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
13 Nov - Approved Q2/H1 Sept 30, 2025 results; appointed Amar Singh as Additional Executive Director from 13.11.2025, Rs6 lakh p.a.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On 13.11.2025
13 Nov - Approved Q2/H1 results (30 Sep 2025); appointed Amar Singh Additional Executive Director (w.e.f.13.11.2025) Rs.6L p.a.
-
Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2025
13 Nov - Unaudited Q2/H1 results (30 Sep 2025); appointed Amar Singh as Additional Executive Director from 13 Nov 2025, Rs.6 lakh p.a.
-
Board Meeting Intimation for 1. Un-Audited Financial Results And Limited Review Report (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2025.
2. Any Other Business With The Permission Of The Chair.
10 Nov - Board meeting 13 Nov 2025 to approve Q2/H1 unaudited results and limited review.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
18 Oct - Compliance as per Reg 74(5) of SEBI (Depositories and Participants), Regulations, 2018 for the Quarter ended 30th September, 2025
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
DCL is in the business of:
a) Pharma:
Manufacturing and trading of Pharmaceutical products
b) Consultancy:
It also provides consultancy services